Establishment of a rapid method for detection of influenza A/B virus' antigens.
10.3760/cma.j.cn112150-20230411-00280
- Author:
Xi Rong WANG
1
;
Sen LI
2
;
Ji Ye LIU
2
;
Bing GU
3
;
Zhi Jun JIA
4
;
Bo TANG
5
Author Information
1. Medical Technology School of Xuzhou Medical University, Xuzhou 221004, China.
2. Nanjing Vazyme Medical Technology Co., Ltd, Nanjing 210000, China.
3. Department of Laboratory Medicine, Guangdong Provincial people's Hospital, Guangzhou 510080, China.
4. Department of Nuclear Medicine, the Drum Tower Hospital Affiliated to the Medical School of Nanjing University, Nanjing 210000, China.
5. Medical Technology School of Xuzhou Medical University, Xuzhou 221004, China Nanjing Vazyme Medical Technology Co., Ltd, Nanjing 210000, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Mice;
Humans;
Influenza, Human/diagnosis*;
Herpesvirus 1, Cercopithecine;
COVID-19;
Sensitivity and Specificity;
Influenza B virus
- From:
Chinese Journal of Preventive Medicine
2023;57(10):1608-1612
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to develop a rapid and convenient test card for simultaneous detection of influenza A and influenza B viruses using quantum dot-based immunochromatographic assay. The test card consists of a test strip and a plastic casing. The test strip is composed of absorbent paper, a buffer pad, nitrocellulose membrane (NC membrane), sample pad, quantum dot-labeled antibody pad, and polyvinyl chloride (PVC) board. The NC membrane is coated with mouse monoclonal antibodies against influenza A and influenza B viruses for the T lines (test lines), and reference proteins A and B for the C line (control line). The quantum dot-labeled antibody pad contains mouse monoclonal antibody-quantum dot conjugates against influenza A and influenza B viruses. The results showed that the detection limit of the test card for both viruses ranged from 1.51 ×102 to 2.71×103 TCID50/ml, indicating its sensitivity for accurate detection of influenza A and influenza B viruses without being affected by various variants. The test card exhibited specific reactions with different subtypes of influenza A and influenza B virus culture fluids and showed no cross-reactivity with adenovirus, novel coronavirus, Mycoplasma pneumoniae, respiratory syncytial virus, Staphylococcus aureus, and other pathogens. Overall, the sensitivity and specificity of the test card for simultaneous detection of influenza A and influenza B viruses meet the requirements for clinical use. It offers the advantages of simplicity, rapidity, and no requirement for special equipment, enabling quick auxiliary diagnosis to prevent disease transmission.
